

AMENDMENTS TO THE CLAIMS:

The following listing replaces all prior versions of the claims:

1-16. (Canceled)

17. (Previously presented) A method for the treatment and prophylaxis of respiratory diseases, allergic diseases, asthma and/or chronic obstructive pulmonary diseases comprising the step of administering loteprednol or a pharmaceutically acceptable ester thereof and N-(3,5-dichloropyridin-4-yl)-2-[1-(4-fluorobenzyl)-5-hydroxyindol-3-yl]-2-oxoacetamide (DFHO) or a pharmaceutically acceptable salt thereof to a subject in need of treatment.

18. (New) The method as claimed in claim 17, wherein administration is oral.

19. (New) The method as claimed in claim 17, wherein administration is topical.

20. (New) The method as claimed in claim 17, wherein the loteprednol or pharmaceutically acceptable ester thereof and N-(3,5-dichloropyridin-4-yl)-2-[1-(4-fluorobenzyl)-5-hydroxyindol-3-yl]-2-oxoacetamide (DFHO) or pharmaceutically acceptable salt thereof are administered simultaneously, sequentially or separately from one another, intranasally or by inhalation.

21. (New) The method as claimed in claim 17, wherein the loteprednol or pharmaceutically acceptable ester thereof and N-(3,5-dichloropyridin-4-yl)-2-[1-(4-fluorobenzyl)-5-hydroxyindol-3-yl]-2-oxoacetamide (DFHO) or pharmaceutically acceptable salt thereof are administered as an inhalable liquid or solid preparation.

22. (New) The method as claimed in claim 17, wherein one of the loteprednol or pharmaceutically acceptable ester thereof and N-(3,5-dichloropyridin-4-yl)-2-[1-(4-fluorobenzyl)-5-hydroxyindol-3-yl]-2-oxoacetamide (DFHO) or pharmaceutically acceptable salt thereof is administered orally and one is administered topically.

23. (New) The method as claimed in claim 17, wherein the N-(3,5-dichloropyridin-4-yl)-2-[1-(4-fluorobenzyl)-5-hydroxyindol-3-yl]-2-oxoacetamide (DFHO) or pharmaceutically acceptable salt thereof is administered orally.